Improving the results of coronary angioplasty.
Coronary angioplasty has changed dramatically in the past three years with major reductions in suboptimal results and restenosis rates, and improvements in safety, efficacy and cost-effectiveness. Intracoronary stent implantation with optimisation of strut expansion and the abandonment of anticoagulants after deployment, have led to less entry-site complications, facilitated early hospital discharge, virtually abolished subacute stent thrombosis and resulted in a 50% reduction in target vessel revascularisation. Adjuvant medical treatment with anti-platelet agents, including glycoprotein IIb/IIIa receptor inhibitors, improves the safety of angioplasty and may further reduce the restenosis rate. Selective use of debulking devices has extended the indications for angioplasty. High resolution fluoroscopy, quantitative coronary angiography and intracoronary ultrasound leading to improved diagnosis, equipment selection and treatment have contributed to better outcomes. Further clinical trials will compare angioplasty and stent implantation with coronary bypass surgery in patients with multivessel coronary disease, and may extend the indications for percutaneous transluminal coronary angioplasty (PTCA) to selected patients with three vessel disease.
Aroney
C N
CN
Prince Charles Hospital, Brisbane, Qld.
D015906:Angioplasty, Balloon, Coronary / Q000379:methods / Q000592:standards / Q000639:trends; D017073:Atherectomy / Q000379:methods / Q000592:standards / Q000639:trends; D019917:Blood Vessel Prosthesis Implantation / Q000379:methods / Q000592:standards / Q000639:trends; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D012449:Safety; D016896:Treatment Outcome
D005343:Fibrinolytic Agents